Growth of transgenic <i>D</i>. <i>parva</i> and control after one month. حسب Lingru Ruan (18995544)

الموضوعات:

Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. حسب Lingru Ruan (18995544)

الموضوعات:

Sociodemographic, occupational, workability characteristics among diabetic workers. حسب Sarah A. Bolbol (21702891)

الموضوعات:

Contents of chlorophyll a, chlorophyll b (Chl a, Chl b) and carotenoid in <i>D</i>. <i>parva</i> cells under treatment of various concentrations of MeJA and GA3. حسب Lingru Ruan (18995544)

الموضوعات:

Fig 2 - حسب Lingru Ruan (18995544)

الموضوعات:

Sequence of <i>DpAP2</i> promoter. حسب Lingru Ruan (18995544)

الموضوعات:

Correlation between workability and laboratory findings of diabetic workers. حسب Sarah A. Bolbol (21702891)

الموضوعات:

Amplification of <i>DpAP2</i> full-length cDNA. حسب Lingru Ruan (18995544)

الموضوعات:

Verification of transgenic <i>D</i>. <i>parva</i>. حسب Lingru Ruan (18995544)

الموضوعات:

Association between workability and laboratory findings of diabetic workers. حسب Sarah A. Bolbol (21702891)

الموضوعات:

Construction of transgenic <i>D</i>. <i>parva</i> overexpressing <i>DpAP2</i> gene. حسب Lingru Ruan (18995544)

الموضوعات:

Fig 4 - حسب Lingru Ruan (18995544)

الموضوعات:

Sociodemographic, occupational, and clinical risk factors associated with low workability and results of Logistic regression analysis among diabetic workers. حسب Sarah A. Bolbol (21702891)

الموضوعات:

Carotenoid contents of control and transgenic <i>D</i>. <i>parva</i>. حسب Lingru Ruan (18995544)

الموضوعات:

Association between workability and clinical characteristics of diabetic workers. حسب Sarah A. Bolbol (21702891)

الموضوعات:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. حسب Claire M. Douglas (21238238)

الموضوعات:

Participant demographic and clinical characteristics. حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... حسب Claire M. Douglas (21238238)

الموضوعات: